AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage iii cancer cervix: Initial results of an IAEA multicentre randomized trial (Record no. 29299)

000 -LEADER
fixed length control field 01969pab a2200337 454500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 150901b2005 xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency Tata Memorial Hospital
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title English
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number
Item number
245 ## - TITLE STATEMENT
Title AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage iii cancer cervix: Initial results of an IAEA multicentre randomized trial
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 2005
300 ## - PHYSICAL DESCRIPTION
Extent 75-78
490 ## - SERIES STATEMENT
Series statement
Volume/sequential designation Vol 1 Issues 2
520 ## - SUMMARY, ETC.
Summary, etc. PURPOSE : AK-2123, a nitrotriazole hypoxic cell sensitizer has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage IIIA and IIIB. MATERIALS AND METHODS : A total of 333 patients were randomised between May1995 and December1998. Patients were randomised to either standard radical treatment (radiation therapy alone, RT) or standard radical radiotherapy and additional administration of AK-2123 (RT+AK-2123). The total dose of 45-50.8 Gy was delivered in 20 to 28 fractions over 4 to 5 1/2 weeks. The dose to the central disease was escalated to a radiobiologically equivalent dose of 70 Gy by external beam or brachytherapy, in accordance with each centres individual practice. In the study arm, patients received 0.6 g/sqm AK-2123 by intravenous administra
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cervical cancer,
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Hypoxic radiosensitizer
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Radiotherapy
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Tatsuzaki H
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kagiya TV
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Okkan S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kizilbash NA
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Jayatilake RS
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Huigol NG
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name werner.dobrowsky@nuth.nhs.uk
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Dobrowsky W
773 ## - HOST ITEM ENTRY
Host Biblionumber 78381
Main entry heading Journal of Cancer Research and Therapeutics
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
a Apr-Jun
907 ## - LOCAL DATA ELEMENT G, LDG (RLIN)
a India
907 ## - LOCAL DATA ELEMENT G, LDG (RLIN)
a Original Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Permanent Location Current Location Date acquired Cost, normal purchase price Full call number Barcode Date last seen Price effective from Koha item type
        Tata Memorial Hospital Tata Memorial Hospital 2007-11-28 0.00 AR7569 2015-09-02 2015-09-02 Articles

Powered by Koha